Table 1 Basic information of NSCLC without COPD and NSCLC with COPD patients
Characteristics | Total | NSCLC without COPD | NSCLC with COPD | P |
|---|---|---|---|---|
n = 230 | n = 170 | n = 60 | ||
Gender | 0.077 | |||
Male | 214 (93.0) | 155 (91.2) | 59 (98.3) | |
Female | 16 (7.0) | 15 (8.8) | 1 (1.7) | |
Age | 64.0 [58.0;68.0] | 64.0 [58.0;68.0] | 65.0 [60.0;69.0] | 0.072 |
Pathology | 0.058 | |||
LUAD | 59 (25.7) | 49 (28.8) | 10 (16.7) | |
LUSC | 135 (58.7) | 92 (54.1) | 43 (71.7) | |
Others | 36 (15.6) | 29 (17.1) | 7 (11.6) | |
Neoadjuvant regimen | 0.346 | |||
Immunotherapy only | 1 (0.5) | 1 (0.6) | 0 (0.0) | |
Immuno + Chemotherapy | 214 (93.0) | 157 (92.4) | 57 (95.0) | |
Immuno + Targeted/Anti-vascular therapy | 8 (3.5) | 5 (2.9) | 3 (5.0) | |
Immuno + Chemo + Targeted therapy | 7 (3.0) | 7 (4.1) | 0 (0.0) | |
Pathologic response | 0.004 | |||
Non-MPR | 110 (47.8) | 91 (53.5) | 19 (31.7) | |
MPR | 120 (52.2) | 79 (46.5) | 41 (68.3) | |
Clinical stage | 0.044 | |||
I/II | 65 (28.3) | 42 (24.7) | 23 (38.3) | |
III | 165 (71.7) | 128 (75.3) | 37 (61.7) | |
Treatment cycles | 3.0 [2.0;4.0] | 3.0 [2.0;4.0] | 3.0 [2.0;4.0] | 0.778 |
Smoking history | 0.227 | |||
No | 15 (6.5) | 14 (8.2) | 1 (1.7) | |
Yes | 179 (77.8) | 129 (75.9) | 50 (83.3) | |
Unknown | 36 (15.7) | 27 (15.9) | 9 (15.0) | |
FEV1 | 2.4 [1.9;2.8] | 2.5 [2.2;2.9] | 1.9 [1.6;2.2] | <0.001 |
FEV1% | 87.7 [74.3;98.1] | 92.1 [83.3;102.0] | 67.3 [56.2;75.6] | <0.001 |
PD-L1 expression | 0.748 | |||
PD-L1 < 50% | 123 (53.5) | 93 (54.7) | 30 (50.0) | |
PD-L1 ≥ 50% | 29 (12.6) | 20 (11.8) | 9 (15.0) | |
Unknown | 78 (33.9) | 57 (33.5) | 21 (35.0) |